THRESHOLD PHARMACEUTICALS, INC.
Merrimack Pharmaceuticals (NASDAQ: MACK) may be the perfect biotech company for your speculative portfolio. The company had its Initial Public Offering in March of 2012 and raised $100 million for its operations. The sale of the public offering was at $7 dollars a share, valuing the company at $647 million. Merrimack seems to have come to market at the right time, as it currently has eight drugs in it's more »
I had a chat with Senior Analyst and Managing Director George Zavoico of MLV & Co. He’s an interesting guy, and he’s worked in the industry at both big pharma and small biotech companies. His ideas are worth hearing and heeding, as he has twice received The Financial Times/Starmine Award for being among the top-ranked earnings estimators in biotech. Each time we talk, Zavoico presents an interesting list more »
Sometimes an analyst issues a revised outlook or changes his/her rating, but does not inform investors of the reasons behind the call. These typically move stocks on the call alone; the price target and outlook. However, some analysts provide detailed reasons behind the call; these are the outlooks that should be noted and used as part of your fundamental research. Therefore, I am taking a look at such outlooks more »
For the most part, there was very little movement in the biotechnology industry on Friday. It was a slow day as almost every stock trading in a range of 2% lower to 2% higher. However, there were a few that saw major movement, and in this article I am looking at those select few.
Sarepta Therapeutics (NASDAQ: SRPT)
I bought shares of Sarepta back in November at $25.50, and more »
Biotechnology can be one of the most volatile industries to be invested in. A lot of the time, investors can own shares in various companies and not even know there is an event coming up. This article will serve to inform investors of 6 biotechnology stocks that have upcoming catalysts in 2013. These catalysts are likely to have a significant impact upon each company.
1) Celsion Corporation (NASDAQ: CLSN)
Celsion more »
In a 13G filing last week, billionaire fund manager Thomas Steyer of Farallon Capital Management announced that his firm now had 5.4% ownership of Horizon Pharma (NASDAQ: HZNP) after buying almost 1.9 million shares. Steyer founded Farallon in 1986, and previously worked for Goldman Sachs and Morgan Stanley.
The Farallon news came in conjunction with other recent reports that notable pharmaceutical investors Tang Capital and Sutter Hill Ventures more »
By George S. Mack, The Life Sciences Report
For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.
I had an opportunity to ask George Zavoico a few questions for The Life Sciences Report. Zavoico is senior biotechnology analyst at the boutique investment bank, MLV & Co. He originally got his career underway as a research scientist and worked in big pharma at more »
George S. Mack, The Life Sciences Report
Oncology Drugs Rack Up Gains
I love finding out how people move from point A to point B in their careers. It was an incremental process for George Zavoico who is today a senior equity analyst at New York City-based MLV & Co., a boutique investment bank focusing on the small cap space. Armed with his Ph.D. in physiology, Zavoico loves the research more »
A year ago, PDL BioPharma, Inc. (NASDAQ: PDLI) announced that it would be switching from its previous special dividend program to a regular dividend program, with $0.15 dividends to be paid out quarterly. Today, this company has a high dividend yield of more than 5% and P/E stands at about 8.6. In this article, I am going to examine the effect this change in dividend policy has more »